Do analysts rate CPHI or UTZ?

Utz Brands has a consensus price target of $13.39, suggesting a potential downside of 6.16%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts plainly believe Utz Brands is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Utz Brands 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CPHI or UTZ more profitable?

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Utz Brands -2.00% 8.97% 4.32%

Does the media prefer CPHI or UTZ?

In the previous week, Utz Brands had 10 more articles in the media than China Pharma. MarketBeat recorded 11 mentions for Utz Brands and 1 mentions for China Pharma. Utz Brands' average media sentiment score of 0.69 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Utz Brands 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CPHI or VTVT?

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 74.64%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media refer more to CPHI or VTVT?

In the previous week, vTv Therapeutics had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for China Pharma. vTv Therapeutics' average media sentiment score of 1.48 beat China Pharma's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CPHI or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CPHI or RFL?

China Pharma has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China Pharma $3.91M 8.36 -$3.08M -$0.43 N/A Rafael $920K 130.28 -$30.52M -$0.68 N/A

Is CPHI or RFL more profitable?

China Pharma has a net margin of -85.56% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Rafael -3,321.74% -41.27% -35.32%

Do analysts prefer VANI or CPHI?

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 195.28%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vivani Medical is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor VANI or CPHI?

In the previous week, Vivani Medical had 2 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Vivani Medical and 1 mentions for China Pharma. Vivani Medical's average media sentiment score of 0.83 beat China Pharma's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CPHI or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CPHI or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than China Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China Pharma $3.91M 8.36 -$3.08M -$0.43 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Does the media refer more to CPHI or RFAI?

In the previous week, RF Acquisition Corp II had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for RF Acquisition Corp II and 1 mentions for China Pharma. RF Acquisition Corp II's average media sentiment score of 0.47 beat China Pharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RF Acquisition Corp II 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

China Pharma (CPHI) Competitors

$0.76 0.00 (-0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.00 (+0.62%)

As of 09/11/2026 07:30 PM Eastern

Compare

CPHI vs. UTZ, VTVT, RFL, VANI, and RFAI

Should you buy China Pharma stock or one of its competitors? China Pharma's main competitors and comparable companies include Utz Brands (UTZ), vTv Therapeutics (VTVT), Rafael (RFL), Vivani Medical (VANI), and RF Acquisition Corp II (RFAI). Companies are selected based on similarities in market, industry, and size.

How does China Pharma compare to Utz Brands?

China Pharma (NYSE:CPHI) and Utz Brands (NYSE:UTZ) are related companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Utz Brands had 10 more articles in the media than China Pharma. MarketBeat recorded 11 mentions for Utz Brands and 1 mentions for China Pharma. Utz Brands' average media sentiment score of 0.69 beat China Pharma's score of 0.00 indicating that Utz Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Utz Brands	3 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Utz Brands has a consensus price target of $13.39, suggesting a potential downside of 6.16%. Given Utz Brands' stronger consensus rating and higher probable upside, analysts plainly believe Utz Brands is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Utz Brands	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.0% of Utz Brands shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 12.7% of Utz Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Utz Brands has higher revenue and earnings than China Pharma. Utz Brands is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	8.36	-$3.08M	-$0.43	N/A
Utz Brands	$1.44B	1.43	$800K	-$0.33	N/A

China Pharma has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Utz Brands has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Utz Brands has a net margin of -2.00% compared to China Pharma's net margin of -85.56%. Utz Brands' return on equity of 8.97% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Utz Brands	-2.00%	8.97%	4.32%

Summary

Utz Brands beats China Pharma on 13 of the 16 factors compared between the two stocks.

How does China Pharma compare to vTv Therapeutics?

China Pharma (NYSE:CPHI) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

vTv Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. vTv Therapeutics' return on equity of -6.27% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
vTv Therapeutics	N/A	-6.27%	-5.06%

China Pharma has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	8.36	-$3.08M	-$0.43	N/A
vTv Therapeutics	$1.02M	123.49	-$26.97M	-$1.06	N/A

China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

vTv Therapeutics has a consensus target price of $55.83, indicating a potential upside of 74.64%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, vTv Therapeutics had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for China Pharma. vTv Therapeutics' average media sentiment score of 1.48 beat China Pharma's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

vTv Therapeutics beats China Pharma on 11 of the 17 factors compared between the two stocks.

How does China Pharma compare to Rafael?

China Pharma (NYSE:CPHI) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

China Pharma has a net margin of -85.56% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Rafael	-3,321.74%	-41.27%	-35.32%

China Pharma has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Rafael has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

11.3% of Rafael shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

China Pharma has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	8.36	-$3.08M	-$0.43	N/A
Rafael	$920K	130.28	-$30.52M	-$0.68	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, China Pharma and China Pharma both had 1 articles in the media. China Pharma's average media sentiment score of 0.00 beat Rafael's score of -1.00 indicating that China Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
China Pharma	Neutral
Rafael	Negative

Summary

China Pharma beats Rafael on 8 of the 13 factors compared between the two stocks.

How does China Pharma compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

6.8% of Vivani Medical shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vivani Medical has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
China Pharma	-85.56%	-63.93%	-31.42%

Vivani Medical has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 195.28%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Vivani Medical is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Vivani Medical had 2 more articles in the media than China Pharma. MarketBeat recorded 3 mentions for Vivani Medical and 1 mentions for China Pharma. Vivani Medical's average media sentiment score of 0.83 beat China Pharma's score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

China Pharma has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
China Pharma	$3.91M	8.36	-$3.08M	-$0.43	N/A

Summary

Vivani Medical beats China Pharma on 10 of the 15 factors compared between the two stocks.

How does China Pharma compare to RF Acquisition Corp II?

China Pharma (NYSE:CPHI) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

RF Acquisition Corp II has lower revenue, but higher earnings than China Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.91M	8.36	-$3.08M	-$0.43	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

In the previous week, RF Acquisition Corp II had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for RF Acquisition Corp II and 1 mentions for China Pharma. RF Acquisition Corp II's average media sentiment score of 0.47 beat China Pharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RF Acquisition Corp II	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RF Acquisition Corp II has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. RF Acquisition Corp II's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
RF Acquisition Corp II	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

China Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Summary

RF Acquisition Corp II beats China Pharma on 7 of the 8 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$32.83M	$12.41B	$7.16B	$23.37B
Dividend Yield	N/A	2.64%	2.57%	3.56%
P/E Ratio	-1.77	799.75	274.94	28.72
Price / Sales	8.36	966.93	686.57	20.04
Price / Cash	N/A	88.17	76.65	34.17
Price / Book	1.09	10.39	10.33	4.74
Net Income	-$3.08M	$2.85B	$3.50B	$1.07B
7 Day Performance	-7.29%	-3.61%	-3.32%	-2.00%
1 Month Performance	-30.25%	0.72%	-0.53%	-3.20%
1 Year Performance	-58.15%	3.61%	23.51%	10.51%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.76 -0.4%	N/A	-58.2%	$32.83M	$3.91M	N/A	250
UTZ Utz Brands	2.1298 of 5 stars	$14.24 +0.1%	$13.39 -6.0%	+10.4%	$2.05B	$1.44B	N/A	3,300	News Coverage Dividend Announcement
VTVT vTv Therapeutics	3.6078 of 5 stars	$31.86 -4.3%	$55.83 +75.2%	+61.1%	$131.13M	$1.02M	N/A	9	Positive News
RFL Rafael	0.1519 of 5 stars	$2.39 +4.2%	N/A	+70.7%	$119.08M	$920K	N/A	20	Negative News Short Interest Increase
VANI Vivani Medical	4.0826 of 5 stars	$1.25 -4.9%	$3.75 +200.0%	+5.0%	$118.62M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. UTZ, VTVT, RFL, VANI, and RFAI

How does China Pharma compare to Utz Brands?

Summary

How does China Pharma compare to vTv Therapeutics?

Summary

How does China Pharma compare to Rafael?

Summary

How does China Pharma compare to Vivani Medical?

Summary

How does China Pharma compare to RF Acquisition Corp II?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. UTZ, VTVT, RFL, VANI, and RFAI

How does China Pharma compare to Utz Brands?

Does the media prefer CPHI or UTZ?

Do analysts rate CPHI or UTZ?

Do institutionals & insiders hold more shares of CPHI or UTZ?

Which has stronger valuation & earnings, CPHI or UTZ?

Which has more volatility & risk, CPHI or UTZ?

Is CPHI or UTZ more profitable?

Summary

How does China Pharma compare to vTv Therapeutics?

Is CPHI or VTVT more profitable?

Which has stronger earnings & valuation, CPHI or VTVT?

Which has more volatility and risk, CPHI or VTVT?

Do analysts rate CPHI or VTVT?

Does the media refer more to CPHI or VTVT?

Do insiders & institutionals believe in CPHI or VTVT?

Summary

How does China Pharma compare to Rafael?

Is CPHI or RFL more profitable?

Which has more volatility and risk, CPHI or RFL?

Do institutionals & insiders hold more shares of CPHI or RFL?

Which has preferable valuation and earnings, CPHI or RFL?

Do analysts rate CPHI or RFL?

Does the media favor CPHI or RFL?

Summary

How does China Pharma compare to Vivani Medical?

Do institutionals & insiders believe in VANI or CPHI?

Is VANI or CPHI more profitable?

Which has more volatility & risk, VANI or CPHI?

Do analysts prefer VANI or CPHI?

Does the media favor VANI or CPHI?

Which has higher earnings & valuation, VANI or CPHI?

Summary

How does China Pharma compare to RF Acquisition Corp II?

Which has preferable earnings and valuation, CPHI or RFAI?

Does the media refer more to CPHI or RFAI?

Is CPHI or RFAI more profitable?

Do analysts recommend CPHI or RFAI?

Which has more risk and volatility, CPHI or RFAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools